Zymeworks Turns Profitable On $250 Million Ziihera Milestone And Raises Its Revenue Outlook

The higher forecast depends on Roche antitrust clearance, while Theravance acquisition costs pushed selling and administrative expenses higher.

Share
Zymeworks Turns Profitable On $250 Million Ziihera Milestone And Raises Its Revenue Outlook

Zymeworks, which develops antibody-based medicines and earns revenue from licensed healthcare assets, posted a $173.7 million third-quarter profit after earning a $250 million milestone tied to Ziihera's U.S. approval. Monday's earnings release also raised its annual revenue outlook, though that forecast depends on antitrust clearance for its Roche collaboration.

Ziihera Changes The Quarter's Math

Revenue reached $256.5 million, compared with $27.6 million a year earlier. The approval milestone from Jazz Pharmaceuticals was the main driver, turning a year-earlier $19.6 million loss into profit; Zymeworks received the payment in October.

The milestone followed August approval of Ziihera-containing treatments for first-line HER2-positive advanced gastroesophageal adenocarcinoma. A $25 million Johnson & Johnson development milestone had contributed to the year-earlier quarter's revenue.

Ziihera royalties were $2.3 million, mostly from Jazz's U.S. sales. Jazz and BeOne Medicines commercialize the antibody through global partnerships, giving Zymeworks royalties and milestone opportunities alongside its own cancer and autoimmune research.

Higher Guidance Depends On Roche

Zymeworks now expects 2026 revenue of $337 million–$351 million, versus $278 million–$292 million previously. It also lifted its adjusted earnings forecast before interest, taxes, depreciation and amortization to $176 million–$190 million from $114 million–$128 million, excluding future transactions.

The company expects antitrust clearance for the Roche collaboration during the fourth quarter. Under the agreement signed October 22, Roche received exclusive worldwide rights to experimental cancer drug ZW209. Zymeworks is eligible for $55 million upfront, and Roche will fund the initial early-stage trial and take responsibility for subsequent global development and commercialization.

Kenneth Galbraith, Zymeworks' chair and chief executive officer, described the financing approach: “Just as importantly, we can increasingly match the capital and ownership structure to each opportunity, whether acquiring and operating a business, partnering an asset, licensing a program or bringing in external venture capital, without assuming that every opportunity must be funded entirely from our balance sheet.”

Theravance Adds Revenue And Costs

Zymeworks completed its purchase of Theravance Biopharma on September 23, adding recurring commercial cash flow from YUPELRI. Theravance supplied approximately $1.5 million of revenue during seven days of ownership in the quarter.

Selling and administrative expenses reached $42.7 million, versus $14.1 million a year earlier. Acquisition-related severance and professional fees were the main causes, together with higher stock-based pay. Research spending was $36.1 million, compared with $35.6 million.

Zymeworks expects to eliminate $13 million–$15 million in annualized overhead and corporate costs following the acquisition. Net other expense was $4.4 million, versus $3.8 million of income a year earlier, principally because of interest on its March Royalty Pharma financing and lower investment income.

The company bought back 534,381 shares for $14 million during the quarter. Across the first nine months, it repurchased 5,737,790 shares for $140.4 million. Zymeworks said $600 million of financing through notes, including royalty-backed debt, supported the acquisition and repurchases while limiting equity dilution.

Zymeworks plans to discuss its research portfolio at an R&D Day in New York on February 11, 2027.

Sources

More on Zymeworks

All Zymeworks (ZYME) coverage →